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http://dx.doi.org/10.1016/j.bgm.201Abstract Hepatocellular carcinoma (HCC) is the most common malignant liver tumor. The
purpose of this study is to characterize proteins secreted from the HepG2 cells, which may
relate to cell differentiation and tumor metastasis. In the proteomic analysis, the secretome
was identified by nano-higheperformance liquid chromatography/electrospray ionization tan-
dem mass spectrometry (nano-HPLC/ESIMS/MS) followed by peptide fragmentation pattern
analysis. In this study, three proteins, p130Cas-associated protein (p130Cas/BCAR1), TAR
DNA-binding protein 43 (TDP43/TARDBP) and translationally controlled tumor protein (TCTP/
TPT1), were identified and confirmed by Western blotting, which showed significantlyof Medical Imaging and Radiological Sciences, Kaohsiung Medical University 100, Shi-Chuan 1st Road,
tw (Y.-C. Tyan).
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Secretome markers for hepatocellular carcinoma 97differential expression compared with the normal liver cells. Analyzing differential protein ex-
pressions in HepG2 cell by proteomic approaches suggests that p130Cas/BCAR1, TDP43/
TARDBP and TCTP/TPT1 as key proteins and may serve as biomarkers for HCC.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the most or second most
common cause of cancer-related mortality, especially in Asia
and Africa, with a 5-year survival rate of less than 5% without
treatment.1 A chronic infection with the hepatitis B virus or
hepatitis C virus increases the risk of developing HCC.2,3
Measurement of serum alpha-fetoprotein (AFP) is widely
used as a serology tumor marker for HCC, with a level
exceeding 500 mg/L considered to be a positive indicator.4
Unfortunately, not all HCCs (e.g., the fibrolamellar type)
secrete AFP, and levels of it are often elevated during preg-
nancy, in tumors of gonadal origin, and even during acute or
chronic viral hepatitis (chronic hepatitis B or chronic hepatitis
C).5,6 Biomarker identification remains a major challenge in
current HCC research for early diagnosis.7
Secreted proteins, referred to as the secretome, are an
important class of proteins that control and regulate a number
of biological and physiological processes,making it a clinically
relevant source for biomarkers and therapeutic target dis-
coveries. To enhance our understanding of the hepatocellular
carcinoma proteome, secretome of HepG2 cells was analyzed
by proteomic approaches. This study is designed to establish
an optimal technique for a proteomic map of hepatocellular
carcinoma proteins. The database provides not only informa-
tion obtained from HepG2 cell secretome proteins of hepa-
tocellular carcinoma, but also potential diagnostic protein
biomarkers for further investigation.Materials and methods
Cell culture
HepG2 (liver tumor cell) and CCL-13 (liver normal cell) cells
were maintained at 37 C and 5% CO2 in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS, Hyclone Laboratories, Logan, UT, USA),
1% penicillin/streptomycin (Gibco) and 44mM NaHCO3.
After 3 days, the cells were washed with phosphate buff-
ered saline (PBS) and the medium was replaced with serum-
free RPMI 1640 medium for 12 hours.Figure 1 (A) Immunoreactive bands of p130Cas/BCAR1,
TDP43/TARDBP, TCTP/TPT1 and b-actin from HepG2 and CCL-
13 cells. (B) Protein expression data are calculated after
normalizing with b-actin. Data are expressed as ratio of
mean  standard error and the asterisk denotes a significant
difference compared with CCL-13 at p < 0.05 (N Z 4).Sample preparation
After incubation with serum-free RPMI 1640 medium, the
secreted proteins in the medium of HepG2 and CCL-13 cells
were centrifuged at 1500 g for 10 minutes at 4 C. The
supernatants were filtered by 0.8-mm filter and the protein
concentrations were adjusted to 1 mg/mL by 25mM
ammonium bicarbonate.Cell secretome samples (100 mL) were reduced, alky-
lated, and then digested with trypsin using standard pro-
tocols. Two microliters of formic acid were added to each
sample prior to the mass spectrometric analysis for protein
identification.
Proteomic analysis
The complex peptide mixtures were separated by reverse-
phase higheperformance liquid chromatography/electro
spray ionization tandem mass spectrometry (RP-nano-HPLC-
ESIMS/MS). The protein tryptic digestswere fractionated using
a flow rate of 400 nL/min with a nano-HPLC system
98 M.-H. Yang et al.(nanoACQUITY UPLC, Waters, Milford, MA, USA) coupled to an
ion trap mass spectrometer (LTQ Orbitrap Discovery Hybrid
FTMS, Thermo, San Jose, CA, USA) equipped with an electro-
spray ionization source. For RP-nano-HPLC-ESI-MS/MS, a
sample (2 mL) of thedesiredpeptidedigestwas loaded into the
reverse phase column (Symmetry C18, Waters, Milford, MA,
USA, 5 mm, 180 mm  20 mm) by autosampler. The RP sepa-
rationwas performed using a linear acetonitrile gradient from
99%buffer A (100%D.I.water/0.1% formic acid) to 85%buffer B
(100% acetonitrile/0.1% formic acid) in 100 minutes using the
micropump. The separation is performed on a C18 micro-
capillary column (BEH C18, Waters, Milford, MA, USA, 1.7 mm,
75 mm  100 mm) using the nano separation system. As pep-
tides eluted from the microcapillary column, they were elec-
trosprayed into the ESI MS/MS with the application of a distal
2.1 kV spraying voltage with heated capillary temperature of
200 C. Each cycle of one full scan mass spectrum (m/z
400e2000) was followed by four data dependent tandemmass
spectra with collision energy set at 35%.
Database search
For protein identification, Mascot software (version 2.2.1;
Matrix Science, London, UK) was used to search the Swiss-
Prot human protein sequence database. Positive protein
identifications were defined when Mowse scores greater
than 100 were considered significant (p < 0.05). Proteins
were annotated by similar searches using UniProtKB/Swiss-
Prot databases.Figure 2 The protein-protein interaction networks were analyz
BCAR1, TDP43/TARDBP, and TCTP/TPT1, are marked by boxes.Western blot
Western blot analysis was applied to detect candidate
proteins, and quantitative analysis of Western blotting
was carried out using the ImageQuant-TL-7.0 software,
version 2010 (Amersham Biosciences, Belgium). Proteins
were separated with 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, with 100 mg of pro-
tein loaded in each lane. Gels were equilibrated for 10
minutes in a transfer buffer and then electroblotted on
nitrocellulose membranes for 75 minutes at 100 V. Mem-
branes were incubated with 1 mg/mL of primary anti-
bodies for 60 minutes and with a 1:10,000 dilution of
secondary antibody for 30 minutes. Next, the membranes
were exposed to an X-ray film prior to later development.
Afterward, the membranes were stripped and probed
with anti-b-actin antibodies for normalization. The pro-
teineprotein interaction pathways were performed by
String 9.0 Web software.Results
In this study,weperformedproteomic approaches to identify
differently secreted proteins between HepG2 cell and CCL-
13 cell. A database search initially suggested 213 differen-
tially expressed proteins. Most of them were identified at
minimal confidence level in which only one unique peptide
sequence matched, whereas 21 protein identificationsed using String 9.0 Web software. Three proteins, p130Cas/
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peptide sequences matched. Three of 21 proteins exhibited
significantly higher levels expressed in the culturemediumof
HepG2 cells compared with that of CCL-13 cells. The three
proteins including p130Cas/BCAR1, TDP43/TARDBP, and
TCTP/TPT1 were involved in cell differentiation and cell
cycle regulation. The results ofWestern blotting showed that
expression of p130Cas/BCAR1, TDP43/TARDBP, and TCTP/
TPT1 in HepG2 cells was at least 1.5-folds (p< 0.05) of that in
CCL-13 cells (Fig. 1). The protein-interacted networks
analyzed by String 9.0 Web software showed the interacted
proteins of p130Cas/BCAR1, TDP43/TARDBP, andTCTP/TPT1
in cells (Fig. 2). Thus, the biological significance between
increase in the secretionof the threeproteins and liver tumor
progression could be further studied accordingly.
Discussion
Theproteinconstitutively secretedbyaparticular typeofcells
in vitro is referred to as the secretome. In this study, we use
the mass spectrometry technique as an analysis method for
determining liver cancer biomarkers on tumor cell secretome.
The cell model was used to identify the tumor progression-
related proteins, which are secreted into the serum-free cul-
turemedium. Secreted proteinsmay coordinatemany cellular
processes in tumor cells, including growth, division, differen-
tiation, apoptosis, migration, and adhesion, thereby contrib-
uting to the growth and spread of the tumor cells. Thus, the
identification of secreted proteomics in tumor cells provides
potential biomarkers closely related to carcinogenesis. More-
over, disease-specific protein biomarkers allow us to define
prognosis of disease and gain deep insight into disease mech-
anisms by which proteins play a major role. Studies on secre-
tomes fromdifferent tumor cellsmayfindnovel biomarkers. In
this study, our data suggest that p130Cas/BCAR1, TDP43/
TARDBP, and TCTP/TPT1 notably express and secrete into the
culturemedium of HepG2 cells. The p130Cas was identified by
Matsuda8 in 1990 and originally introduced as a highly phos-
phorylated protein in cell transformations of the Src (pp60v-
Src) and Crk (p47gag-Crk) oncogenes. It was a key signal
molecule of the integrin pathway that was included in cell
proliferation, apoptosis, andmigrationmediated by integrin.9
TDP43, a messenger RNA (mRNA)-binding protein, played an
important role in the regulatingmRNAmetabolism,which was
involved in transcriptional repression, exon skipping, and RNA
splicing.10 TCTP was initially identified in mammalian tumor
cells and controlled the posttranscriptional modification. It
was multi-involved in division cellular processes, such as
apoptosis, microtubule organization, ion homeostasis, and
interacting proteins in the PLK1 protein kinase.11 Thus, thepotential utility of the three proteins as liver cancer bio-
markers merits study in the future.
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